Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease

被引:14
作者
Helmer, Catherine
Andrieu, Sandrine
Peres, Karine
Orgogozo, Jean-Marc
Vellas, Bruno
Dartigues, Jean-Francois
机构
[1] Univ Bordeaux 2, INSERM, U593, FR-33076 Bordeaux, France
[2] CHU Bordeaux, Federat Neurol, Bordeaux, France
[3] INSERM, U558, Toulouse, France
[4] CHU, Toulouse, France
关键词
ADAS-cog score; predictive value; Alzheimer's disease;
D O I
10.1159/000098516
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 [法学]; 0303 [社会学]; 100203 [老年医学];
摘要
Background/Aims: To determine the predictive value of the 6-month evolution of the ADAS-cog score in initially mild to moderate Alzheimer's disease (AD) patients on the risk of death or severe dementia (MMSE < 10) within 2 years. Methods: Cognition was assessed every 6 months using the ADAS-cog scale in the Real. fr study, a cohort of AD patients. Six classes of ADAS-cog evolution were distinguished, from the severest deterioration ( decline 6 7 points) to the greatest cognitive improvement ( gain 6 4 points). Results: Among 536 AD patients, 53 (9.9%) had a 6-month decline of 7 points or more. This group with the severest deterioration was significantly associated with the risk of severe dementia or death at 2 years ( relative risk, RR = 3.8, 95% confidence interval, Cl = 2.1-6.8), even after adjustment for baseline MMSE, disability and ADAS-cog score ( RR = 2.6, 95% CI = 1.4-5.0). In addition, subjects with a decline by at least 4 points were also at greater risk of severe dementia. Conclusion: These results confirm the value of the ADAS-cog scale as a judgement criterion in clinical trials since it is a good surrogate marker of long-term prognosis. The proportion of fast decliners on the ADAS-cog could be a helpful judgement criterion for future trials in AD. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 22 条
[1]
Cholinesterase inhibitors for Alzheimer's disease [J].
Birks, J .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)
[2]
Commenges D, 1998, STAT MED, V17, P1973, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1973::AID-SIM892>3.0.CO
[3]
2-5
[4]
European Medicine Evaluation Agency (EMEA), 1997, NOT GUID MED PROD TR
[5]
The staging and assessment of moderate to severe Alzheimer disease [J].
Feldman, HH ;
Woodward, M .
NEUROLOGY, 2005, 65 (06) :S10-S17
[6]
MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[7]
*FOOD DRUG COSM RE, 1992, FDA GUID ALZ DRUG DI, P13
[8]
Gillette-Guyonnet S, 2003, J Nutr Health Aging, V7, P91
[9]
Donepezil for severe Alzheimers disease [J].
Hogan, DB .
LANCET, 2006, 367 (9516) :1031-1032
[10]
Rate of cognitive decline and mortality in Alzheimer's disease [J].
Hui, JS ;
Wilson, RS ;
Bennett, DA ;
Bienias, JL ;
Gilley, DW ;
Evans, DA .
NEUROLOGY, 2003, 61 (10) :1356-1361